JP2012504112A - フィラデルフィア陰性骨髄増殖性症候群のケアのためのヒストンデアセチラーゼ阻害剤の使用 - Google Patents

フィラデルフィア陰性骨髄増殖性症候群のケアのためのヒストンデアセチラーゼ阻害剤の使用 Download PDF

Info

Publication number
JP2012504112A
JP2012504112A JP2011528301A JP2011528301A JP2012504112A JP 2012504112 A JP2012504112 A JP 2012504112A JP 2011528301 A JP2011528301 A JP 2011528301A JP 2011528301 A JP2011528301 A JP 2011528301A JP 2012504112 A JP2012504112 A JP 2012504112A
Authority
JP
Japan
Prior art keywords
hydroxycarbamoyl
methyl
diethyl
phenylcarbamoyloxymethyl
ammonium chloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011528301A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012504112A5 (enExample
Inventor
オルドーニ ティツィアーノ
マスカーニ パオロ
ランバルディ アレッサンドロ
バルブイ ティツィアーノ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Italfarmaco SpA
Original Assignee
Italfarmaco SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco SpA filed Critical Italfarmaco SpA
Publication of JP2012504112A publication Critical patent/JP2012504112A/ja
Publication of JP2012504112A5 publication Critical patent/JP2012504112A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2011528301A 2008-09-29 2009-09-21 フィラデルフィア陰性骨髄増殖性症候群のケアのためのヒストンデアセチラーゼ阻害剤の使用 Pending JP2012504112A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ITMI2008A001720A IT1392908B1 (it) 2008-09-29 2008-09-29 Uso degli inibitori delle istone-deacetilasi per la cura di sindromi mieloproliferative philadelphia-negative
ITMI2008A001720 2008-09-29
US19328308P 2008-11-13 2008-11-13
US61/193,283 2008-11-13
PCT/EP2009/062214 WO2010034693A1 (en) 2008-09-29 2009-09-21 Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes

Publications (2)

Publication Number Publication Date
JP2012504112A true JP2012504112A (ja) 2012-02-16
JP2012504112A5 JP2012504112A5 (enExample) 2012-08-02

Family

ID=40810309

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011528301A Pending JP2012504112A (ja) 2008-09-29 2009-09-21 フィラデルフィア陰性骨髄増殖性症候群のケアのためのヒストンデアセチラーゼ阻害剤の使用

Country Status (17)

Country Link
US (4) US20110294892A1 (enExample)
EP (1) EP2344253B1 (enExample)
JP (1) JP2012504112A (enExample)
KR (3) KR20160096721A (enExample)
CN (1) CN102164638A (enExample)
BR (1) BRPI0913699A2 (enExample)
CA (1) CA2738081C (enExample)
CY (1) CY1115255T1 (enExample)
DK (1) DK2344253T3 (enExample)
ES (1) ES2478827T3 (enExample)
HR (1) HRP20140499T1 (enExample)
IT (1) IT1392908B1 (enExample)
PL (1) PL2344253T3 (enExample)
PT (1) PT2344253E (enExample)
SI (1) SI2344253T1 (enExample)
SM (1) SMT201400087B (enExample)
WO (1) WO2010034693A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8217079B2 (en) * 2010-03-26 2012-07-10 Italfarmaco Spa Method for treating Philadelphia-negative myeloproliferative syndromes
WO2015165975A1 (en) * 2014-04-29 2015-11-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating myeloid neoplasias
TW201821105A (zh) 2016-10-20 2018-06-16 美商弗瑪治療公司 使用ｈｄａｃ１１抑制劑之方法
US10865328B2 (en) * 2017-02-20 2020-12-15 Dow Silicones Corporation Room-temperature-curable silicone composition and electric/electronic apparatus
US11535607B2 (en) 2018-04-20 2022-12-27 Valo Health, Inc. Isoindolines as HDAC inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006515028A (ja) * 2003-01-17 2006-05-18 イタルフアルマコ・ソチエタ・ペル・アチオニ ４−ヒドロキシカルバモイルフェニル）−カルバミン酸（６−ジエチルアミノメチル−ナフタレン−２−イル）エステルの塩酸一水和物
WO2008082646A2 (en) * 2006-12-28 2008-07-10 The Johns Hopkins University Histone deacetylase inhibitors, combination therapies and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
IT1283637B1 (it) 1996-05-14 1998-04-23 Italfarmaco Spa Composti ad attivita' antinfiammatoria ed immunosoppressiva
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
ITMI20030064A1 (it) * 2003-01-17 2004-07-18 Italfarmaco Spa Uso dei derivati dell'acido idrossamico per la preparazione
US7244751B2 (en) 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
WO2006063294A2 (en) * 2004-12-09 2006-06-15 Kalypsys, Inc. Novel inhibitors of histone deacetylase for the treatment of disease
TW200730485A (en) * 2005-07-29 2007-08-16 Kalypsys Inc Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
AU2006321710A1 (en) 2005-12-09 2007-06-14 Massachusetts Institute Of Technology Methods for identifying and targeting tumor stem cells based on nuclear morphology
US20080242648A1 (en) * 2006-11-10 2008-10-02 Syndax Pharmaceuticals, Inc., A California Corporation COMBINATION OF ERa+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006515028A (ja) * 2003-01-17 2006-05-18 イタルフアルマコ・ソチエタ・ペル・アチオニ ４−ヒドロキシカルバモイルフェニル）−カルバミン酸（６−ジエチルアミノメチル−ナフタレン−２−イル）エステルの塩酸一水和物
WO2008082646A2 (en) * 2006-12-28 2008-07-10 The Johns Hopkins University Histone deacetylase inhibitors, combination therapies and methods of use

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN5012000340; ＧＵＥＲＩＮＩ　ＶＩＴＴＯＲＩＡ: 'ＰＯＴＥＮＴ　ＩＮＨＩＢＩＴＩＯＮ　ＯＦ　ＥＥＣ　ＣＯＬＯＮＹ　ＦＯＲＭＡＴＩＯＮ　ＩＮ　ＪＡＫ２（Ｖ６１７Ｆ）　ＰＶ　ＡＮＤ　ＥＴ　ＢＹ　ＬＯＷ　ＤＯＳＥＳ　以下備考' ＢＬＯＯＤ Ｖ１０８　Ｎ１１　ＰＡＲＴ．１, 200611, Ｐ７６４Ａ *
JPN5012000341; ＧＵＥＲＩＮＩ　Ｖ: 'ＴＨＥ　ＨＩＳＴＯＮＥ　ＤＥＡＣＥＴＹＬＡＳＥ　ＩＮＨＩＢＩＴＯＲ　ＩＴＦ２３５７　ＳＥＬＥＣＴＩＶＥＬＹ　ＴＡＲＧＥＴＳ　ＣＥＬＬＳ　ＢＥＡＲＩＮＧ　ＭＵＴＡＴＥＤ　ＪＡＫ２　（Ｖ６１７Ｆ）' ＬＥＵＫＥＭＩＡ　（ＢＡＳＩＮＧＳＴＯＫＥ） Ｖ２２　Ｎ４, 200804, Ｐ７４０-７４７ *
JPN5012000342; ＧＵＥＲＩＮＩ　ＶＩＴＴＯＲＩＡ: 'ＳＥＬＥＣＴＩＶＥ　ＴＡＲＧＥＴＩＮＧ　ＯＦ　ＴＨＥ　ＪＡＫ２（Ｖ６１７Ｆ）　ＭＵＴＡＴＩＯＮ　ＩＮ　ＰＯＬＹＣＹＴＨＥＭＩＡ　ＶＥＲＡ　以下備考' ＢＬＯＯＤ Ｖ１１０　Ｎ１１　ＰＡＲＴ．１, 200711, Ｐ１７０Ａ-１７１Ａ *
JPN6013050289; 'Ａ　Ｐｈａｓｅ　ＩＩ　Ｍｕｌｔｉｐｌｅ　Ｄｏｓｅ　Ｃｌｉｎｉｃａｌ　Ｔｒｉａｌ　ｏｆ　Ｈｉｓｔｏｎｅ　Ｄｅａｃｅｔｙｌａｓｅ　Ｉｎｈｉｂｉｔｏｒ　ＩＴＦ２３５７　ｉｎ　Ｐａｔｉｅｎｔｓ　ｗｉｔｈ　Ｒｅ' Ｂｌｏｏｄ Ｖｏｌ．１１０，　Ｎｏ．１１，　ｐａｒｔ１．, 2007, ｐｐ．３５６Ａ *
JPN7013003745; Ｈａｅｍａｔｏｌｏｇｉｃａ-　ｔｈｅ　ｈｅｍａｔｏｌｏｇｙ　ｊｏｕｒｎａｌ Ｖｏｌ．９３，　Ｓｕｐｐｌ．１, 200806, ｐ．２４４ *

Also Published As

Publication number Publication date
HRP20140499T1 (hr) 2014-07-04
US20110294892A1 (en) 2011-12-01
IT1392908B1 (it) 2012-04-02
US20210128512A1 (en) 2021-05-06
US9522127B2 (en) 2016-12-20
EP2344253A1 (en) 2011-07-20
ITMI20081720A1 (it) 2010-03-30
ES2478827T3 (es) 2014-07-23
KR20160096721A (ko) 2016-08-16
KR20110069075A (ko) 2011-06-22
EP2344253B1 (en) 2014-04-23
BRPI0913699A2 (pt) 2017-06-13
CA2738081C (en) 2017-11-07
US20170049740A1 (en) 2017-02-23
PT2344253E (pt) 2014-07-16
SMT201400087B (it) 2014-09-08
US20140039059A1 (en) 2014-02-06
PL2344253T3 (pl) 2014-09-30
DK2344253T3 (da) 2014-06-16
SI2344253T1 (sl) 2014-08-29
CA2738081A1 (en) 2010-04-01
WO2010034693A1 (en) 2010-04-01
CY1115255T1 (el) 2017-01-04
CN102164638A (zh) 2011-08-24
KR20170124640A (ko) 2017-11-10

Similar Documents

Publication Publication Date Title
US20210128512A1 (en) Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes
KR102496146B1 (ko) 노화 세포를 사멸시키고 노화 관련 질환 및 장애를 치료하기 위한 방법 및 조성물
ES2908026T3 (es) Composiciones y procedimientos para la expansión y el cultivo de células madre epiteliales
US20200325148A1 (en) Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
JP2005525345A (ja) Ｔｒｘ媒介性疾患を処置する方法
JP2021506765A (ja) Ｄｕｘ４の発現に関連する疾患の治療のための化合物
CN103608012A (zh) 在癌症如骨髓增殖性肿瘤治疗中的帕比司他与鲁索利替尼的组合
CN103619168A (zh) 用于治疗白血病的组合物、方法和药盒
US8748464B2 (en) Use of SIRT1 activators or inhibitors to modulate an immune response
US8933071B2 (en) Dimethyl fasudil for inducing polyploidization of megakaryocytes and for treating blood and bone marrow diseases and disorders
US8217079B2 (en) Method for treating Philadelphia-negative myeloproliferative syndromes
JP2022504184A (ja) ブドウ膜黒色腫の治療のための併用療法
JP2020520385A (ja) 癌治療のための薬剤の組み合わせ
WO2025059029A1 (en) Methods of treating vexas syndrome
JP2021187831A (ja) Ｓ−ヒドロキシクロロキンを用いたエリテマトーデスの治療
TW202038960A (zh) Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物
ES2239529B1 (es) Procedimiento de identificacion de los compuestos reguladores de la actividad tubulina desacetilasa de hdac6 y sus aplicaciones.
CN114786661A (zh) 青蒿素化合物、5-氨基酮戊酸或甲基-5-氨基酮戊酸和化疗剂的药物组合
ES3028375T3 (en) 1,2-dihydroquinoline-2-ones for their use in the treatment of limb-girdle muscular dystrophy
US8546382B2 (en) Methods for enhancing hematopoietic progenitor cell engraftment
WO2018006689A1 (zh) 氟维司群在制备治疗无功能垂体腺瘤的药物中的用途
ES2589169B1 (es) Uso de la pentoxifilina y de una composición farmacéutica para elaborar un medicamento para prevenir el envejecimiento prematuro en humanos
CN121445740A (zh) Gsk2879552在制备治疗或缓解心脏病的药物中的应用
TW202502341A (zh) 哌啶烯類化合物在製備治療癌症的藥物中的應用
WO2017194031A1 (zh) 蛋白功能抑制剂dapt在制备治疗肿瘤的药物中的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140115

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140408

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20140811

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140811